arrow
A

Adrían Alegre

idibaps
H指数:48
被引数:9,831

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

High-risk features of early relapse in newly-diagnosed multiple myeloma: The impact of cytogenetics and response to initial therapy

新诊断多发性骨髓瘤早期复发的危险因素:细胞遗传学和初始治疗反应的影响

2025-04-240
OAAI
Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease

新诊断的移植不合格的多发性骨髓瘤患者的免疫麻痹恢复,这是补充最小残留疾病的独立预后因素

2024-10-230
PRE
Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome inpatients with high-risk smoldering multiple myeloma included in the GEM-CESAR trial

通过质谱分析周围残留疾病的单点和动力学,以预测gem-cesar试验中包括的高危阴燃性多发性骨髓瘤患者的结局

2024-07-110
OAAI
Biological relapse in multiple myeloma: Outcome and treatment strategies in a Spanish real-world setting
2024-07-040
OAAI
The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression

用强化策略治疗的高危阴燃骨髓瘤患者的基因组分析揭示了耐药和进展的潜在标志物

2024-04-290
OAAI
Real-World Outcomes of Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results of a Spanish Expanded Access Program (EAP)
2022-12-127
OAAI
A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma
2022-04-1911
OAAI
Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial
2021-05-2116
OAAI
Daratumumab Monotherapy for Relapsed or Refractory Multiple Myeloma: Results of an Early Access Treatment Protocol in Europe and Russia

Daratumumab单药治疗复发或难治性多发性骨髓瘤: 欧洲和俄罗斯早期治疗方案的结果

2021-02-254
OAAI
Agreement Between 18F-FDG PET/CT and Whole-Body Magnetic Resonance Compared With Skeletal Survey for Initial Staging and Response at End-of-Treatment Evaluation of Patients With Multiple Myeloma

18F-FDG PET/CT与全身磁共振与骨骼检查之间的一致性,以评估多发性骨髓瘤患者的初始分期和治疗结束时的反应

2021-01-2913
OAAI
Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study
2020-10-08180
OAAI
Results of an Early Access Treatment Protocol of Daratumumab Monotherapy in Spanish Patients With Relapsed or Refractory Multiple Myeloma
2020-06-033
OAAI
Treatment with daratumumab in patients with relapsed/refractory AL amyloidosis: a multicentric retrospective study and review of the literature
2020-02-2829
PREAI
Melflufen in patients (pts) with relapsed/refractory multiple myeloma (RRMM) refractory to daratumumab (dara) and/or pomalidomide (pom) (OP-106)
2019-07-010
PRE
Analysis of renal impairment in MM-003, a phase III study of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in refractory or relapsed and refractory multiple myeloma
2016-04-1419
OAAI
Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone
2015-08-0661
OAAI